PHARMA MAR, S.A. financials
PHARMA MAR, S.A.
Country: ES Reporting currency: EUR Latest annual report: 2024-12-31
LEI:
959800QWKZ45ZQC2AV58 Financial statements
(EUR, as reported — unscaled; 109 line items across 2 annual periods)
| Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Cost of sales | €8.2M | €9.6M |
| Gross profit | €166.7M | €148.5M |
| Administrative expenses | €24.4M | €18.3M |
| Operating profit (EBIT) | €6.5M | -€3.8M |
| Net finance income / (cost) | €5.5M | €204.0K |
| Finance costs | €8.5M | €9.4M |
| Profit before tax | €12.0M | -€3.6M |
| Income tax expense | -€14.1M | -€4.8M |
| Profit for the year | €26.1M | €1.1M |
| — attributable to owners | €26.1M | €1.1M |
| Total comprehensive income | €26.1M | €1.2M |
| Per share | ||
| Basic EPS | €1.49 | €0.06 |
| Diluted EPS | €1.49 | €0.06 |
| Free cash flow / share | €-0.51 | €-1.49 |
| Cash flow statement | ||
| Net cash from operating activities | €6.0M | -€13.4M |
| Net cash from investing activities | €1.0M | -€43.0M |
| Purchase of PP&E (capex) | €15.0M | €14.8M |
| Net cash from financing activities | -€5.3M | -€32.1M |
| Dividends paid | €11.4M | €11.7M |
| Proceeds from borrowings | €15.4M | €4.9M |
| Repayments of borrowings | €6.5M | €6.3M |
| Net change in cash | €3.2M | -€89.8M |
| Balance sheet | ||
| Total assets | €349.6M | €340.5M |
| Non-current assets | €99.4M | €87.9M |
| Property, plant & equipment | €55.9M | €43.9M |
| Right-of-use assets | €3.2M | €3.7M |
| Current assets | €250.2M | €252.6M |
| Inventories | €52.0M | €39.3M |
| Trade & other receivables | €34.7M | €27.6M |
| Cash & equivalents | €63.2M | €60.0M |
| Total equity | €208.4M | €193.4M |
| — attributable to owners | €208.4M | €193.4M |
| Non-current liabilities | €58.6M | €51.2M |
| Long-term borrowings | €39.9M | €27.0M |
| Lease liabilities (non-current) | €1.4M | €1.8M |
| Current liabilities | €82.7M | €95.9M |
| Lease liabilities (current) | €8.0M | €12.8M |
| Trade & other payables | €51.6M | €40.3M |
| Derived metrics | ||
| Free cash flow | -€9.0M | -€28.3M |
| Operating margin | 3.7% | -2.4% |
| Net margin | 14.9% | 0.7% |
| Return on equity | 12.5% | 0.6% |
| Cash conversion ratio | 0.23× | -11.83× |
| Capex coverage | 0.40× | -0.91× |
| Other reported items | ||
| Adjustments For Decrease Increase In Inventories | €12.7M | €11.5M |
| Adjustments For Decrease Increase In Trade Account Receivable | €7.3M | -€1.8M |
| Adjustments For Depreciation and Amortisation Expense | €6.8M | €5.8M |
| Adjustments For Finance Costs | €2.5M | €2.4M |
| Adjustments For Finance Income | -€5.7M | -€4.1M |
| Adjustments For Gain Loss On Disposals Property Plant and Equipment | -€837.0K | €1.9M |
| Adjustments For Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss Property Plant and Equipment | -€284.0K | -€1.7M |
| Adjustments For Increase Decrease In Trade Account Payable | -€11.2M | -€3.4M |
| Adjustments For Provisions | €196.0K | -€99.0K |
| Adjustments For Sharebased Payments | €0 | €297.0K |
| Adjustments For Unrealised Foreign Exchange Losses Gains | -€2.3M | €1.7M |
| Cash Flows From Used In Operations Before Changes In Working Capital | -€664.0K | €6.8M |
| Comprehensive Income Attributable To Owners of Parent | €26.1M | €1.2M |
| Current Advances To Suppliers | €1.7M | €2.9M |
| Current Borrowings and Current Portion of Noncurrent Borrowings | €3.4M | €3.4M |
| Current Deferred Income Including Current Contract Liabilities | €4.0M | €24.9M |
| Current Financial Assets At Amortised Cost | €91.3M | €102.5M |
| Deferred Tax Assets | €36.0M | €31.5M |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | €1.5M | -€1.2M |
| Equity and Liabilities | €349.6M | €340.5M |
| Finance Income | €14.0M | €9.6M |
| Gains Losses On Exchange Differences On Translation Net of Tax | €5.0K | €35.0K |
| Gains Losses On Financial Assets Measured At Fair Value Through Other Comprehensive Income Net of Tax | €1.0K | -€4.0K |
| Impairment Loss On Financial Assets | -€217.0K | -€271.0K |
| Income Taxes Paid Refund Classified As Financing Activities | €2.1M | €2.0M |
| Income Taxes Paid Refund Classified As Operating Activities | -€23.3M | -€16.6M |
| Increase Decrease In Working Capital | -€31.7M | -€34.9M |
| Increase Decrease Through Changes In Ownership Interests In Subsidiaries That Do Not Result In Loss of Control | -€68.0K | -€3.0K |
| Increase Decrease Through Sharebased Payment Transactions | €776.0K | €28.0K |
| Increase Decrease Through Transfers and Other Changes Equity | €5.0K | €35.0K |
| Increase Decrease Through Treasury Share Transactions | -€18.6M | -€34.1M |
| Inflows of Cash From Investing Activities | €368.0M | €287.2M |
| Intangible Assets Other Than Goodwill | €1.0M | €1.9M |
| Interest Paid Classified As Operating Activities | €2.5M | €2.4M |
| Interest Received Classified As Operating Activities | €5.7M | €4.1M |
| Investment Property | €845.0K | €845.0K |
| Issued Capital | €10.9M | €11.0M |
| Liabilities | €141.3M | €147.1M |
| Licence Fee Income | €46.5M | €33.6M |
| Miscellaneous Other Operating Expense | €13.4M | €12.8M |
| Noncurrent Government Grants | €1.3M | €2.3M |
| Other Adjustments To Reconcile Profit Loss | -€14.0K | -€32.0K |
| Other Comprehensive Income | €6.0K | €31.0K |
| Other Current Liabilities | €13.9M | €12.5M |
| Other Gains Losses | €3.7M | €1.3M |
| Other Inflows Outflows of Cash Classified As Investing Activities | €0 | €0 |
| Other Noncurrent Financial Assets | €2.5M | €6.1M |
| Other Noncurrent Liabilities | €194.0K | €193.0K |
| Other Provisions | €1.9M | €2.0M |
| Other Reserves | €16.0K | €15.0K |
| Outflows of Cash From Investing Activities | €367.0M | €330.3M |
| Payments To Acquire Or Redeem Entitys Shares | €18.6M | €37.9M |
| Proceeds From Issuing Other Equity Instruments | €18.9M | €18.6M |
| Proceeds From Sales of Property Plant and Equipment Classified As Investing Activities | €888.0K | €0 |
| Purchase of Property Plant and Equipment Intangible Assets Other Than Goodwill Investment Property and Other Noncurrent Assets | €495.0K | €1.1M |
| Receipts From Premiums and Claims Annuities and Other Policy Benefits | -€938.0K | €2.3M |
| Research and Development Expense | €103.5M | €99.3M |
| Retained Earnings | €168.4M | €142.2M |
| Revenue From Contracts With Customers | €174.9M | €158.2M |
| Revenue From Rendering of Services | €448.0K | €512.0K |
| Revenue From Royalties | €61.3M | €52.2M |
| Revenue From Sale of Goods | €66.5M | €71.9M |
| Selling Expense | €22.8M | €23.5M |
| Share Premium | €59.9M | €71.3M |
| Treasury Shares | €30.8M | €31.1M |
Methodology
Every line item above is a fact tagged in PHARMA MAR, S.A.'s annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.